Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TransThera Starts China Combination Trial of Lead Drug in GI Cancers

publication date: May 26, 2021

TransThera, a clinical stage Nanjing biopharma, will partner with Roche to test a combination therapy for China patients with gastrointestinal tract cancers. The companies will conduct a trial of TransThera's TT-00420 and Roche's anti-PD-L1, Tencentriq (atezolizumab). TT-00420 is novel small molecule kinase inhibitor. In a Phase I trial it showed preliminary clinical benefits in Cholangiocarcinoma patients and other GI cancer patients. It also appears to modulate the tumor microenvironment, which makes it an attractive partner for checkpoint inhibitors in hard-to-treat solid tumors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital